drug
as of 2026-07-01Levetiracetam
MeSH D000077287
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Hannover Medical School
5 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Trials
5
Investigating the Effect of a Single-dose of Levetiracetam on Brain Function, Chemistry and Cognitive Performance in Psychosis Risk
NCT06224530—Recruiting
Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Schizophrenia
NCT02647437—Completed
Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia
NCT03034356Phase 1, Phase 2Completed
Levetiracetam in Early Psychosis
NCT03129360Phase 2Completed
Pharmacovigilance in Gerontopsychiatric Patients
NCT02374567Phase 3Terminated
KOLs & investigators
5
Donald C. Goff, MDKOL score 8
Gemma Modinos, BSc MSc PhDKOL score 8
Jason R. Tregellas, PhDKOL score 5
Helge Frieling, Prof., MDKOL score 5
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
trial
trial
trial
indication
indication
indication
indication
indication
KOL
Donald C. Goff, MD
personKOL score 8
Gemma Modinos, BSc MSc PhD
personKOL score 8
Jason R. Tregellas, PhD
personKOL score 5
Helge Frieling, Prof., MD
personKOL score 5